Rahul Aggarwal

MD

Developmental therapeutics specialist
Genitourinary oncologist
Cancer researcher and sports enthusiast

Dr. Rahul Aggarwal is a specialist in cancers of the genital and urinary organs. He cares for patients at the UCSF Helen Diller Family Comprehensive Cancer Center. He also serves as director of the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic, which provides comprehensive care to men who are receiving androgen deprivation therapy, hormone therapy for prostate cancer.

As a member of the Developmental Therapeutics Genitourinary Cancer Program, Aggarwal enrolls patients with advanced solid tumor malignancies into early-phase clinical trials of novel targeted treatments. His research focuses on developing hormonal treatment strategies that reduce the toxicity of androgen deprivation therapy for men with advanced prostate cancer. He is also interested in developing new molecular imaging techniques that will help predict how advanced solid tumors will respond to treatment.

Aggarwal earned his medical degree from the Northwestern University Feinberg School of Medicine. At UCSF, he completed an internship and residency in internal medicine, followed by a clinical fellowship in hematology and oncology.

Aggarwal has also been a research fellow in developmental therapeutics at Genentech. He is a member of the American Society of Clinical Oncology (ASCO) and recipient of the ASCO/Conquer Cancer Foundation Young Investigator Award.

  • Education

    Northwestern University Feinberg School of Medicine, 2006

  • Residencies

    UCSF Medical Center, Internal Medicine, 2009

  • Fellowships

    UCSF Medical Center, Hematology/Oncology, 2013

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

    Hematology, American Board of Internal Medicine

  • Academic Title

    Associate Professor

It's an honor to help take care of people with cancer, and I strive each and every day to improve outcomes for our patients.

Conditions I specialize in

Clinics I work with

View map

Center for Neuroendocrine Tumors

Bakar Precision Cancer Medicine Building

1825 Fourth St.
San Francisco, CA 94158

(415) 476-2212
M-F, 8:30 a.m. - 5 p.m.

Genitourinary Medical Oncology Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

(415) 476-4616
M-F, 8 a.m. - 5 p.m.

Prostate Cancer Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

M-F, 8 a.m. - 5 p.m.

My reviews

5.0

Overall Experience
429 Reviews
Dr. Aggarwal is an exceptional health care provider. He listens attentively to everything I say and addresses all my needs and concerns. He is without doubt the best doctor I have had the privilege of treating me.
Explained things in a way that was easy to understand
426 Reviews
Did the doctor pay attention to your concerns
427 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
421 Reviews
Knew the important information about your medical history
425 Reviews
The provider showed respect for what you had to say
423 Reviews
The provider spent enough time with me
427 Reviews
Read all reviews About our process

Selected research

Decorative Caduceus

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant ...

Defined as either objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (complete response (CR), partial response (PR)) or confirmed >= 50% decline from serum prostate-specific antigen (PSA) at ...

Recruiting

Decorative Caduceus

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

Using PARADIGM and DiPSC tools, we will discover the expression and clinical factors that are predictive and correlate with treatment benefit within each treatment cohort.

Recruiting

Decorative Caduceus

Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With C...

The primary endpoint for the study is the proportion of patients with undetectable serum PSA (< 0.2 ng/mL) at 6 months following completion of apalutamide therapy (18 months from date of randomization). Patients who discontinue ap...

Recruiting

Decorative Caduceus

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

The study cohort will be divided into subgroups based on whether or not patient experienced a >= 50% decline from baseline in serum PSA (PSA50 responder) or not (PSA50 non-responder). The mean percent change from baseline in SUVma...

Recruiting

Decorative Caduceus

Phase II Trial of AZD6738 Alone and in Combination With Olaparib

ORR will be measured using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and Will be based on one-sided exact binomial test comparison of the observed ORR in evaluable patients to the null-hypothesized valu...

Recruiting

Decorative Caduceus

A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in ...

Recruiting

Decorative Caduceus

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Progression free survival

Recruiting

Decorative Caduceus

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation ...

Adverse events, serious adverse events, and dose limiting toxicities

Recruiting

Decorative Caduceus

A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRP...

Type, incidence, severity, seriousness, and relatedness of adverse events.

Recruiting

Decorative Caduceus

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Pros...

Will be determined from the aggregate of the safety and efficacy data observed graded by Common Terminology Criteria for Adverse Events (CTCAE).

Recruiting

Contact me

Providers on my team

Share